Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-Week, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multicenter Trial In Overactive Bladder Subjects To Confirm The Efficacy Of 8 Mg Fesoterodine Compared To 4 Mg Fesoterodine.

NCT01302067 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01302067
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01302067 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-Week, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multicenter Trial In Overactive Bladder Subjects To Confirm The Efficacy Of 8 Mg Fesoterodine Compared To 4 Mg Fesoterodine.
Lead sponsor
Pfizer
Phase
Phase 4
Overall status
Completed
Start date
May 31, 2011
Completion date
November 30, 2012
Enrollment
2,012 (actual)
Sites
293

Conditions

As the registry lists them; a condition with its own page is linked.

overactive bladder